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Abstract: Binge-eating behavior involves rapid consumption of highly
palatable foods leading to increased weight gain. Feeding in binge disorders
resembles other compulsive behaviors, many of which are responsive to Nacetylcysteine (NAC), which is a cysteine prodrug often used to promote nonvesicular glutamate release by a cystine–glutamate antiporter. To examine
the potential for NAC to alter a form of compulsive eating, we examined the
impact of NAC on binge eating in a rodent model. Specifically, we monitored
consumption of standard chow and a high-fat, high carbohydrate western diet
(WD) in a rodent limited-access binge paradigm. Before each session, rats
received either a systemic or intraventricular injection of NAC. Both systemic
and central administration of NAC resulted in significant reductions of binge
eating the WD without decreasing standard chow consumption. The reduction
in WD was not attributable to general malaise as NAC did not produce
condition taste aversion. These results are consistent with the clinical
evidence of NAC to reduce or reverse compulsive behaviors, such as, drug
addiction, skin picking and hair pulling.

Introduction
Binge eating is one of the most prevalent eating disorders in the
United States, and contributes to the obesity epidemic that is currently
endangering the health of ~30% of all Americans.1, 2 Feeding in binge
disorders is characterized by rapid consumption of large amounts of
highly palatable food that occur in very short periods of time.3 These
maladaptive alterations in feeding behavior culminate in a destructive
state that often parallels other compulsive disorders, such as drug
addiction.4, 5 In many instances, binge eating is reported to occur in
the absence of hunger, suggesting that this compulsive feeding state
could arise from excessive hedonic drive rather than unmet
homeostatic needs.6, 7
Many compulsive disorders involve abnormal glutamatergic
signaling.8 Likely because of this, the cysteine prodrug Nacetylcysteine (NAC) has been shown to reduce many forms of
compulsive behaviors ranging from addiction to trichotillomania.9, 10
The mechanism of action of NAC typically involves increasing the
activity of the cystine–glutamate antiporter system xc−,11 which has
been shown to be a key component of glutamate homeostasis by
maintaining extrasynaptic glutamate tone via non-vesicular release
and, in turn, affecting receptor function (i.e., synaptic signaling) in
regions implicated in hedonic motivated eating.12, 13 System xc− has
been shown to be an effective target to inhibit cocaine-induced
behaviors and reinstatement in preclinical studies.14 Because of the
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compulsive aspect of binge eating, an overeating behavior analogous
to drug abuse, we examine the potential for systemic or
intraventricular (ICV) administration of NAC to alter binge eating. In
the current study, we utilized a frequently employed preclinical model
of binge eating in which rodents are permitted daily limited access to a
highly palatable food as an adjunct to their ad libitum standard chow
(SC) and recapitulates several characteristics of human binge-eating
disorder.15

Methods
Animals
Male Sprague–Dawley rats (225–250 g; 53–58-days-old;
Harlan; Indianapolis, IN, USA) were housed individually under a 12 h
light/dark cycle (2PM: Lights OFF; 2AM: Lights ON) with ad libitum
access to a Harlan standard diet (8604 formula) for the duration of all
experiments. Intake was monitored daily via a BioDAQ Food Intake
Monitor (Research Diets, New Brunswick, NJ, USA) or by pre-weighing
food bins before and after experimental sessions. Body weights were
also recorded daily. All procedures using animals were approved by the
Marquette University Institutional Animal Care and Use Committee.

Cannulation surgery and microinjections
Animals were anesthetized with a
ketamine/xylazine/acepromazine (77:1.5:1.5 mg−1 ml−1 kg−1;
intraperitoneal (i.p.)) cocktail and placed in a stereotaxic apparatus. A
26 gauge unilateral guide cannula (Plastics One; Roanoke, VA, USA)
was placed into a lateral ventricle and secured to the skull via an
acrylic resin. The stereotaxic coordinates were anterior/posterior,
−0.8 mm from bregma; medial/lateral, ±1.5 mm from midline;
dorsal/ventral, −3.0 mm from the surface of the skull, whereas the
injector extended 0.5 mm further beyond the tip of the guide cannula.
Stereotaxic coordinates were based on The Rat Brain in Stereotaxic
Coordinates, 6th Edition.16
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Limited access binge-eating model
Animals with ad libitum access to SC (Harlan 8604 formula; SC;
32% of total kilocalorie (kcal) protein, 54% of total kcal carbohydrate,
14% of total kcal fat; 3.0 kcal g−1) were additionally allowed daily
limited access (30 min day−1) to a highly palatable western diet (WD;
Research Diets; New Brunswick, NJ, USA; 17% of total kcal protein,
43% of total kcal carbohydrate, 41% of total kcal fat; 4.7 kcal g−1)
shortly after lights out (45 min). Chronic systemic (i.p.; 90 mg kg−1)
and intermittent central (ICV; 10 μg/ 5μl) NAC was administered 45–
60 min before gaining limited access to WD based on previous work
examining the preclinical therapeutic potential of systemic and
centrally administered NAC in attenuating cocaine-relapse behavior in
rodents.17

Chronic systemic NAC
Animals (n=12–17/treatment) received chronic i.p. injections of
either vehicle (saline) or NAC (90 mg kg−1) 45–60 min before gaining
limited access (30 min day−1) to the pre-weighed bin of WD for 14
days.

Central NAC
After a 1 week period of recovery from guide cannula surgery,
animals (n=6–8/dose) were placed on the limited-access binge
paradigm for 7 days during which NAC was injected into the cerebral
ventricles on alternating days. On days 1, 3, 5 and 7 animals received
central infusions of NAC (10 μg/5 μl) whereas control animals received
an equal volume of vehicle (saline); microinjections were preformed
1 h before WD access. Animals were given daily access (30 min day−1)
to WD to avoid associating bin access with any protocol associated
with microinjections.

Conditioned taste aversion
A separate group of animals were habituated to restricted water
access (1 h day−1) and systemic injections (i.p.) of saline 45–60 min
before water access for 1 week. Subsequently, animals were separated
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into three treatment groups (n=5/group): saline, NAC (90 mg kg−1) or
LiCl (2%; i.p.), and offered two bottles each containing a 0.15%
saccharin solution for 24 h then returned to their previous restricted
water conditions. Two days later, animals were provided a two-bottle
choice test with one bottle containing 0.15% saccharin solution and
the other containing water for 1 h.

Statistics
Data are presented as means±standard errors of the mean, and
were analyzed statistically (Sigma Plot 11; Systat Software Inc.; San
Jose, CA, USA) by analysis of variance (with repeated measures when
appropriate) or student’s t-test. Fischer LSD analysis was used for all
post-hoc group comparisons. P values <0.05 were considered
statistically significant.

Results
Daily systemic injections of NAC (90 mg kg−1; i.p.) or vehicle
(saline) injections were administered 45 min before limited access
(30 min day−1) to a highly palatable WD as an adjunct to ad libitum SC
for 14 days. Animals treated with NAC ate significantly less WD (Figure
1a; treatment F(1,405)= 5.478; P<0.03), and significantly more SC
(Figure 1b; treatment F(1,405)=4.893; P<0.04) over the 2 week
study. As expected, NAC-treated animals displayed a significantly
larger percentage of daily kcal ingested from SC and a concomitant
reduction in WD intake than vehicle-treated rats by the 14th day of
experimentation (Figure 1c; left; P<0.05). The compensatory increase
in SC consumption paired with the attenuation in WD consumption
resulted in no significant change in total calories consumed or body
weight gain (Figures 1d and e). In a separate study, NAC administered
centrally every 48 h (before WD access) at the onset of dark via ICV
injections displayed a similar suppression in the escalation of WD
consumption over a 7 day period (Figure 1f; treatment × time, F(6,
97)= 2.281; P<0.05).
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Figure 1.

System (90 mg kg−1; i.p.) and central (10 μg/5μl) NAC alters binge behavior produced
by daily limited access to a palatable food. (a) NAC-treated animals ate significantly
less WD (30 min day−1) compared to saline-injected control animals. (b) Subsequently,
NAC-treated animals ate significantly more SC over the duration of the study. (c)
Percent kcal intake of SC on the 14th day is significantly higher for the NAC-treated
group, whereas WD consumption was significantly decreased compared to the control
group. (d, e) There is no significant difference in cumulative food intake or body
weight gained between the two experimental groups. (f) In a separate study, animals
received infusions (NAC or saline; ICV) 30 min before accessing WD, central
administration of NAC significantly suppressed WD consumption over the 7 day study.
Data expressed as mean±s.e.m. *P<0.05 compared to control group.

The hypophagic effects of NAC appear to be specific to palatable
WD consumption as it does not significantly alter the feeding behavior
of animals maintained on ad ibitum SC only (Figure 2a). Moreover,
there were no effects on SC consumption over the first 6 or 24 h after
administration of NAC (data not shown). In addition, a conditionedtaste aversion revealed that suppression of WD by NAC was not due to
malaise (Figure 2b).
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Figure 2.

Systemic administration of NAC (90 mg kg−1; i.p.) does not alter ad libitum SC
consumption or produce any conditioned-taste aversion. (a) Animals maintained on ad
libitum SC and not subjected to a limited-access binge paradigm show no changes in
feeding behavior measured 1 and 3 h post i.p. injection. (b) Saccharin preference ratio
(%) of control (saline), NAC and LiCl (2% body weight)-treated animals produced only
a significant suppression of saccharin consumption in the LiCl-treated group. Data
expressed as mean±s.e.m. *P<0.05 compared to controls.

Discussion
Chronic systemic NAC significantly attenuates binge eating of a
WD over a 14 day study (Figure 1). Although chronic NAC
administration did not alter total caloric intake or weight gain (Figures
1d and e), systemic or central administration was sufficient to reduce
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intake of highly caloric and palatable food without inducing malaise
(Figures 2b and c). This selectivity of NAC to regulate only WD
consumption is quite notable as it suggests that system xc− activation
does not impact overall caloric homeostasis but may lessen the
hedonic drive for food. Future studies extending chronic NAC
administration beyond 2 weeks may be necessary to demonstrate
effects on long-term calorie consumption and body weight.
NAC, a cysteine prodrug, has been demonstrated to drive the
activity of the cystine–glutamate antiporter system xc−, which
promotes non-vesicular glutamate release and consequently impact
synaptic glutamate signaling, which is critical to the development and
maintenance of a wide variety of compulsive behaviors.18, 19 In the
case of long-term use of drugs of abuse, there is a reduction in system
xc− activity in the nucleus accumbens, which is thought to contribute
to the pathological glutamate signaling that in turn contributes to the
addiction.20 Subsequently, both preclinical and clinical studies of NAC
treatment have shown inhibition of cocaine-induced behaviors in
animals and reduction in craving and/or use of cocaine and tobacco in
humans.9, 20, 21 The effectiveness of NAC to reduce binge eating of a
highly caloric palatable food is consistent with other studies
demonstrating the attenuation of compulsive behaviors, such as, drug
taking, hair pulling and skin picking, and suggests that system xc− is a
potential therapeutic target for the treatment of compulsive feeding
disorders.9, 10, 22 Pursuing effective treatments for compulsive eating
disorders will require further understanding of the neural mechanisms
that underlie hedonic drive.7
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